India rejects BDR Pharma's bid to make generic of Bristol's Sprycel

11/1/2013 | Economic Times (India), The

The Indian Patent Office denied BDR Pharmaceuticals' compulsory licensing application to produce a generic copy of Bristol-Myers Squibb's cancer drug Sprycel, or dasatinib, because it said BDR did not make sufficient efforts to acquire a voluntary license for the drug. "The facts of the case indicate that BDR did not make enough attempts to seek a voluntary license from the innovator company, which went against them," said Chaitanya Prasad, controller general of patents. BDR called the decision unfair, while Bristol-Myers Squibb said "intellectual property protection is important" for innovation.

View Full Article in:

Economic Times (India), The

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Consumer Directed Health Plan (CDH) Product Offering Manager
Blue Cross Blue Shield MA
Quincy, MA
ISHN - Chief Compliance Officer
Mountain States Health Alliance
Johnson City, TN
Actuary
Meridian Health Plan
Detroit, MI
President/Chief Executive Officer
MedCost
Winston-Salem, NC
Director, Payer Marketing
Avalere Health
Washington, DC